Previous 10 | Next 10 |
Kindred Biosciences to Announce Third Quarter 2020 Financial Results Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time on Monday, November 9, 2020. PR Newswire SAN FRANCISCO, Oct. 28, 2020 SAN FRANCISCO , Oct. 28, ...
Vaxart (NASDAQ: VXRT) is gearing up for a potential roll-out of its experimental COVID-19 vaccine. The clinical-stage biotechnology company is expanding its partnership with Kindred Biosciences (NASDAQ: KIN) to manufacture its oral vaccine candidate for the novel coronav...
Vaxart (VXRT) and Centaur Biopharmaceutical Services, a subsidiary of Kindred Biosciences (KIN) have expanded their agreement under which Centaur will manufacture Vaxart's oral vaccine for COVID-19 and other vaccine candidates. Centaur is a full-service contract development and manufacturing ...
Centaur Biopharmaceutical Services Announces Expansion of Manufacturing Agreement with Vaxart for COVID-19 and Other Vaccine Candidates PR Newswire SAN FRANCISCO, Oct. 7, 2020 SAN FRANCISCO , Oct. 7, 2020 /PRNewswire/ -- Centaur Biopharmaceutical Services Inc...
Kindred Biosciences Announces Expansion of Manufacturing Agreement with Vaxart for COVID-19 and Other Vaccine Candidates PR Newswire SAN FRANCISCO, Oct. 7, 2020 SAN FRANCISCO , Oct. 7, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmac...
This article is part of a series that provides an ongoing analysis of the changes made to Ariel Investments’ 13F stock portfolio on a quarterly basis. It is based on Ariel Investments’ regulatory 13F Form filed on 08/14/2020. John Rogers’ 13F portfolio value increased ~1...
Kindred Biosciences (NASDAQ: KIN ) announces positive results from a pivotal efficacy study, evaluating KIND-030, a monoclonal antibody targeting canine parvovirus infection (CPV). More news on: Kindred Biosciences, Inc., Healthcare stocks news, Read more ...
SAN FRANCISCO , Sept. 16, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced positive results from a pivotal efficacy study of KIND-030, a monoclonal antibody targeting cani...
SAN FRANCISCO , Sept. 9, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will participate in the H.C. Wainwright Global Investment Conference on September 14-15 , the Cantor Global Heal...
LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online. Registration details and the company schedule can be seen here: https://ld500.ldmicro.co...
News, Short Squeeze, Breakout and More Instantly...
Kindred Biosciences Inc. Company Name:
KIN Stock Symbol:
NASDAQ Market:
(NewsDirect) Kin Mining NL (ASX:KIN) managing director Andrew Munckton tells Proactive significant assay results have been received from the next four lines of extensional aircore drilling between Cardinia Hill and Collymore within the Eastern Corridor at Cardinia Gold Project. He says the st...
(NewsDirect) Kin Mining NL (ASX:KIN) managing director Andrew Munckton tells Proactive all about the gold stock’s March quarter report. The explorer continued to drill and secure assays for the Cardinia Gold Project’s Helens East and Helens-Rangoon faults — pivotal prospe...
(NewsDirect) Kin Mining NL (ASX:KIN) managing director Andrew Munckton brings Proactive up to speed on the latest gold finds at the Helens-Rangoon fault within Cardinia’s Eastern Corridor. Results from a February drill program confirm that higher-grade, lode-style mineralisation extend...